Travere therapeutics reports first quarter 2024 financial results

Fda grants priority review for snda to convert filspari ® (sparsentan) from accelerated approval to full approval for the treatment of igan in the u.s.; pdufa target action date of september 5, 2024
TVTX Ratings Summary
TVTX Quant Ranking